Thyroid Cancer
This category covers medicines used in the treatment of thyroid cancer, principally the targeted therapies prescribed when the disease is advanced or no longer responds to radioactive iodine. The range includes multikinase inhibitors such as lenvatinib, sorafenib and cabozantinib, the TRK inhibitor larotrectinib for tumours carrying an NTRK gene fusion, and the BRAF/MEK inhibitor trametinib used in combination for specific mutations. Which of these applies depends on the type of thyroid cancer and its molecular profile.
Several are available as generics produced by licensed manufacturers, containing the same active ingredient at the same strength as the branded originals — generic sorafenib, for example, corresponds to branded Nexavar. Because these medicines are typically taken daily over long periods, the cost difference between a branded product and its generic equivalent can be considerable. We compare on active ingredient, strength and formulation alongside price, and make no claims about treatment outcomes.
Thyroid cancer medicines are prescription-only and require specialist oncology supervision, including monitoring for side effects such as raised blood pressure with several of these agents. A valid prescription is required before dispatch, and our team can confirm current pricing and availability for your destination. For broader context on cancer care and generic oncology medicines, visit our cancer medicines hub. Used as prescribed by a licensed medical professional.
